Detection and Quant of Differences in Hodgkin Lymphoma and Diffuse Large B-cell Lymphoma Using Positron Emission Tomography/Computed Tomography (PET/CT)

Not Applicable

Completed

• Conditions: Lymphoma
• Interventions: Radiation: Fludeoxyglucose F18; Procedure: Computed Tomography; Procedure: Positron emission tomography

• Registration Number: NCT01004718
• Lead Sponsor: Abramson Cancer Center at Penn Medicine

Brief Summary

RATIONALE: Imaging procedures, such as positron emission tomography or computed tomography, may help in detecting differences between Hodgkin lymphoma or diffuse large B-cell lymphoma cancer cells. PURPOSE: This clinical trial is studying positron emission tomogaphy and computed tomography in determining differences in Hodgkin lymphoma and diffuse large B-cell lymphoma.

Detailed Description

OBJECTIVES:

I. Assess the feasibility of detection and quantification of differences in the temporal and spatial distribution of FDG uptake between lesions of HL and DLBCL.

OUTLINE:

Patients undergo fludeoxyglucose F18 (FDG) positron emission tomography/computed tomography scans 60 and 180 minutes after FDG administration.

After completion of study, patients are followed for 24 hours.

Study Timeline

• Study Start: 2009-05
• Study First Submitted: 2009-10-29
• Study First Submitted QC: 2009-10-29
• Study First Posted: 2009-10-30
• Primary Completion: 2013-07
• Study Completion: 2014-11-05
• Disposition First Submitted: 2020-04-13
• Disposition First Submitted QC: 2020-04-14
• Disposition First Posted: 2020-04-17
• Results First Submitted: 2020-09-11
• Status Verified: 2021-04
• Results First Submitted QC: 2021-04-27
• Last Update Submitted: 2021-04-27
• Results First Posted: 2021-05-18
• Last Update Posted: 2021-05-18

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 10

Inclusion Criteria

• Subjects with a pathologically-proven diagnosis of classic HL or DLBCL with measurable disease by any imaging technique or physical examination.

Exclusion Criteria

• Pregnant or nursing,
• Uncontrolled diabetes mellitus,
• Active infection,
• Inability to give informed consent or to comply with all study procedures,
• Subjects may be excluded at the discretion of the principal investigator or study team members.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Fludeoxyglucose F18 (FDG) PET/CT scans	Fludeoxyglucose F18	Patients undergo fludeoxyglucose F18 (FDG) positron emission tomography/computed tomography scans and 180 minutes after FDG administration.
Fludeoxyglucose F18 (FDG) PET/CT scans	Computed Tomography	Patients undergo fludeoxyglucose F18 (FDG) positron emission tomography/computed tomography scans and 180 minutes after FDG administration.
Fludeoxyglucose F18 (FDG) PET/CT scans	Positron emission tomography	Patients undergo fludeoxyglucose F18 (FDG) positron emission tomography/computed tomography scans and 180 minutes after FDG administration.

Primary Outcome Measures

Name	Time	Method
Percentage Change in Maximum Lesional FDG Uptake From 60 to 180 Minutes After FDG Administration	2 hours (between 60 minutes post-administration and 180 minutes post-administration)	Lesional fluorodeoxyglucose (FDG) uptake is measured by standardized uptake value (SUV). The study compared the percentage of change in maximum SUV over 2 hours (first measure was 60 minutes post-administration and second timepoint was 180 minutes post-administration).

Trial Locations

Locations (1)

Abramson Cancer Center of the University of Pennsylvania; 🇺🇸 Philadelphia, Pennsylvania, United States